JAGX: חוב לטווח קצר של החברה Jaguar Health, Inc.

The market dynamics of Jaguar Health, Inc. (JAGX) show a current level of 0.12. Jaguar Health, Inc. is developing partnerships with oncology and veterinary centers to promote Mytesi globally. The company relies on the release of plant-based diarrhea treatments for humans and animals. Simultaneously, the R&D division is conducting final clinical trials of crofelemer, expanding the drug's range of applications for chemotherapy.

Institutional capital assesses the attractiveness of Jaguar Health, Inc. (JAGX) through the lens of the company's ability to service current liabilities amid biopharmaceutical market volatility. The dynamics of short-term financial liabilities reflect the total sum of all debts maturing within one year, which becomes a critical indicator of solvency and overall asset reliability given the vulnerability of raw material supply chains.